# US 2010/0136061 A1 · Light-mediated anti-cell proliferative compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136061 A1
- Document ID: US20100136061A1
- Status: Published application
- Kind: A1
- Application number: 12/446,729
- Filed: 2007-10-25
- Published: 2010-06-03
- Earliest claimed: 2006-10-25
- Assignees: La Jolla Institute for Allergy and Immunology
- Inventors: Carl F. Ware; Timothy C. Cheung; Theresia A. Banks
- Web page: https://patentgrep.com/patent/US20100136061A1

## CPC

- C12N 5/067: {Hepatocytes}
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C12N 5/0672: {Stem cells; Progenitor cells; Precursor cells; Oval cells}
- A61K 2039/5152: {Tumor cells}
- A61K 2039/6006: {Cells}
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/33: Insulin
- C12N 2503/02: Drug screening
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The tumor-necrosis factor superfamily member LIGHT (p30; TNFSF-14) is a cytokine for inducing immune responses against tumors. A novel biochemical approach is used to decorate the surface of tumor cells with LIGHT. LIGHT decorated cells can be used to vaccinate and induce effective, sustained immunity against cells expressing neo or pathogen associated antigens. Variants of LIGHT are described that enhance binding to cellular receptors (e.g., LT beta receptor) and decrease regulation by inhibitors (e.g., Decoy Receptor 3) increasing ability to stimulate immunity.

## Claims

### Claim 1

A cell, said cell having an LTbeta receptor agonist attached, conjugated or coupled to the membrane of a cell.

### Claim 2 (depends on 1)

The cell of claim 1, wherein the LTbeta receptor agonist comprises LIGHT (p30 polypeptide), LTalpha1 beta2, LTalpha2 beta1, LTbeta or an LTbeta receptor antibody.

### Claim 3 (depends on 1)

The cell of claim 1, wherein the cell is a hyperproliferative cell.

### Claim 4 (depends on 1)

The cell of claim 1, wherein the cell is a tumor cell, cancer cell, neoplastic cell or metastatic cell.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The cell of claim 1, wherein the cell expresses an antigen selected from a tumor cell or a cancer cell antigen, a neoplastic cell or a metastatic cell antigen, a viral antigen, a bacterial antigen, a fungal antigen, or a parasite antigen.

### Claim 7 (depends on 1)

The cell of claim 1, wherein the LTbeta receptor agonist is not expressed from a nucleic acid in the cell that encodes the LTbeta receptor agonist.

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 1)

The cell of claim 1, wherein the LTbeta receptor agonist is attached, conjugated or coupled to the membrane of a cell via covalent or non-covalent binding of LTbeta receptor agonist to an intermediary molecule, said intermediary molecule covalently or non-covalently bound to a molecule present on the cell membrane.

### Claim 12 (depends on 11)

The cell of claim 11, wherein the intermediary molecule comprises a first moiety and a second moiety.

### Claim 13 (depends on 12)

The cell of claim 12, wherein said first moiety comprises biotin or a biotin derivative.

### Claim 14 (depends on 12)

The cell of claim 12, wherein said second moiety comprises avidin, neutravidin or streptavidin, or a derivative or amino acid variant thereof.

### Claim 15 (depends on 1)

The cell of claim 1, wherein LTbeta receptor agonist binding to the cell membrane occurs via binding to avidin, neutravidin or streptavidin, or a derivative or amino acid variant thereof, wherein said avidin, neutravidin, streptavidin, derivative or amino acid variant thereof is bound to a molecule present on the cell membrane.

### Claim at position 14

-21. (canceled)

### Claim 22 (depends on 1)

The cell of claim 1, wherein the LTbeta receptor agonist is human.

### Claim 23 (depends on 2)

The cell of claim 2, wherein the LIGHT (p30 polypeptide) comprises a full length amino acid sequence.

### Claim 24 (depends on 2)

The cell of claim 2, wherein the LIGHT (p30 polypeptide) comprises an extracellular amino acid sequence of LIGHT.

### Claim at position 18

-29. (canceled)

### Claim 30 (depends on 2)

The cell of claim 2, wherein the LIGHT (p30 polypeptide) comprises a LIGHT (p30 polypeptide) amino acid sequence with reduced affinity for DcR3 (Decoy receptor 3) as compared to native wild type LIGHT (p30 polypeptide).

### Claim 31 (depends on 2)

The cell of claim 2, wherein the LIGHT (p30 polypeptide) comprises a LIGHT (p30 polypeptide) amino acid sequence with greater affinity for LTβR or HVEM as compared to native wild type LIGHT (p30 polypeptide).

### Claim at position 21

-33. (canceled)

### Claim 34 (depends on 1)

The cell of claim 1, wherein the LTbeta receptor agonist has biotin or a biotin derivative attached thereto.

### Claim at position 23

-37. (canceled)

### Claim 38 (depends on 1)

The cell of claim 1, wherein the cell is human.

### Claim at position 25

-41. (canceled)

### Claim 42

A method of promoting, stimulating, inducing or increasing immunity against a hyperproliferative cell, tumor cell, cancer cell or metastatic cell, or pathogen infected cell comprising administering to a subject an amount of a cell having LTbeta receptor agonist attached, conjugated or coupled to the cell membrane effective to promote, stimulate, induce or increase the subject's immunity against the hyperproliferative cell, tumor cell, cancer cell, metastatic cell or pathogen infected cell.

### Claim at position 27

-46. (canceled)

### Claim 47

A method of treating a subject for undesirable or abnormal hyperproliferative cells, tumor cells, cancer cells, neoplastic cells, metastatic cells, or pathogen infected cells comprising administering to the subject an amount of a cell having LTbeta receptor agonist attached, conjugated or coupled to the cell membrane effective to treat the subject for undesirable or abnormal hyperproliferative cells, tumor cells, cancer cells, neoplastic cells, metastatic cells, or pathogen infected cells.

### Claim at position 29

-121. (canceled)
